Clinical Trials Logo

Metastatic Urothelial Carcinoma clinical trials

View clinical trials related to Metastatic Urothelial Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05940844 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Study of OB-002 in Patients With Refractory Metastatic Cancer

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.

NCT ID: NCT03108261 Not yet recruiting - Clinical trials for Metastatic Urothelial Carcinoma

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Start date: May 1, 2017
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and/or TSC2 mutations (changes in deoxyribonucleic acid [DNA]).Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.